The US equity market hit a record high last week before pulling back as concerns surround the impact of the coronavirus on the global manufacturing supply chain intensified. Gold price hits a 7-year high on the back of demand for safe haven assets. Short-term market volatility is expected to continue as the coronavirus spread outside China.



In the news

  • Markets saw volatility across the week, with a mid-week spike for the US market which hit a new high before losing momentum towards the end of the week.
  • Technology stocks took the brunt of the hit after enjoying a strong run since the start of the year.
    • Apple Inc’s report of likely missing its sales forecast on the back of China’s supply disruption put pressure on its stock price. 
    • Investors then took a step back, fearing that Apple Inc was the first of many as negative consequences spread across other companies.
    • Tesla Inc, however, remained resilient and continued to perform well, gaining 14% over the week as investors were adamant that the company remains a leader in electric vehicle manufacturing.
  • China puts in place stimulus measures to support its economy as a negative impact looks imminent:
    • The PBoC slashed its 1-year loan prime rate to 4.05% from 4.15%.
    • 5-year loan rate was reduced from 4.80% to 4.75%.
    • The central bank also injected RMB 100 billion into its money markets via a 7-day repurchase agreement.
  • The China continued to move higher last week, as investors took on a more optimistic approach that the government would provide stimulus measures to support the market.
  • Commodity prices slid lower as economic activity in China slows, coupled with expectations that growth will be weaker for global economies in the interim.
  • Gold price hit a 7-year high last week when it breached the USD1,600 per ounce level after worry of negative consequences from the virus pushed investors into safe haven assets.
  • In Malaysia, the Securities Commission liberalises its regulations to allow Private Retirement Schemes to to invest into Gold Exchange-Traded Funds. 
    • 0828EA, the only physically-backed Gold ETF listed on Bursa, has remained stable amidst the volatility in the global financial markets. The ETF has gained 9.7% in MYR terms this year.


In other economic news

  • US home data picked up with building permits growing by 9.2% -  marking the highest level since March 2007.
  • The EU bloc’s released some encouraging data over the week:
    • Composite PMI climbed to 51.6 in February (from 51.4 in January) with the support of its services component.  The reading came in better than expected.
    • Manufacturing PMI also improved to 49.1 in February, climbing from January’s reading of 47.9
  • The UK also posted some encouraging economic data:
    • Its CPI improved for the 1st time in 6 months with a January reading of 1.8%.
    • Though below the 2% target set by the Bank of England, the inflation reading was an improvement from December’s 1.3%.
    • Job data for 4Q2019 exceeded expectations, with 180,000 new jobs being created as opposed to the 145,000 forecasted.
  • Japan’s preliminary manufacturing PMI signalled a continued contraction with a reading of 47.6, down from the earlier 48.8 in January.
  • Malaysia’s CPI reading for January also failed to meet expectations, when it was reported at 1.6% against the expected 1.7%.



What to look out for ahead?

  • US Feds indicated that rates will likely remain unchanged, but will remain vigilant on the development of the impact from the coronavirus and trade uncertainty.
  • Investors into the Malaysian market are being kept on their toes as new development unfold surrounding the domestic political scene after the surprise resignation of the Prime Minister this afternoon.
  • While global investors may be taking a wait and see approach, investors in China have been optimistic on their domestic equity market – believing that more stimulus measures will be made by the government to boost markets.
    • China’s Foresight Fund recently closed its 2nd equity mutual fund. While it targeted to raise 6 billion Yuan, the Fund managed to raise 120 billion Yuan on its first day.
    • 13 other products had enjoyed similar fund raising, and had to close their subscription period earlier.

To Hedge

  • 0828EAto hedge your portfolio with some Gold exposure.
  • 0833EAa HSCEI Inverse strategy that helps hedge your portfolio against weakness from the performance of China companies listed on the HKex.
  • 0831EAthe NYSE FANG+ Inverse strategy that hedges against the performance of tech stocks listed in the US.


To Add Position

  • 0829EA / 0829EBa strategy that gives investors exposure into the consumer focused sector through China companies listed in HK, and the US
  • 0832EAa 2X leveraged strategy on the HSCEI that captures 2 times the performance of China companies listed on the HKex
  • 0830EAa 2X leveraged strategy on the NYSE FANG+ that captures 2 times the performance of US listed tech stocks – which has since risen by 43.6% YTD.





A look at the performance of the TradePlus ETFs, and major global indices



Learn more about TradePlus ETFs
+(60) 12 606 8685


Disclaimer: This article has been prepared by AHAM Asset Management Berhad (“AHAM Capital”) specific for its use, a specific target audience, and for discussion purposes only. All information contained within this presentation belongs to AHAM Capital and may not be copied, distributed or otherwise disseminated in whole or in part without written consent of AHAM Capital. The information contained in this presentation may include, but is not limited to opinions, analysis, forecasts, projections and expectations (collectively referred to as “Opinions”). Such information has been obtained from various sources including those in the public domain, are merely expressions of belief. Although this presentation has been prepared on the basis of information and/or Opinions that are believed to be correct at the time the presentation was prepared, AHAM Capital makes no expressed or implied warranty as to the accuracy and completeness of any such information and/or Opinions. As with any forms of financial products, the financial product mentioned herein (if any) carries with it various risks. Although attempts have been made to disclose all possible risks involved, the financial product may still be subject to inherent risk that may arise beyond our reasonable contemplation. The financial product may be wholly unsuited for you, if you are adverse to the risk arising out of and/or in connection with the financial product. AHAM Capital is not acting as an advisor or agent to any person to whom this presentation is directed. Such persons must make their own independent assessments of the contents of this presentation, should not treat such content as advice relating to legal, accounting, taxation or investment matters and should consult their own advisers. AHAM Capital and its affiliates may act as a principal and agent in any transaction contemplated by this presentation, or any other transaction connected with any such transaction, and may as a result earn brokerage, commission or other income. Nothing in this presentation is intended to be, or should be construed as an offer to buy or sell, or invitation to subscribe for, any securities. Neither AHAM Capital nor any of its directors, employees or representatives are to have any liability (including liability to any person by reason of negligence or negligent misstatement) from any statement, opinion, information or matter (expressed or implied) arising out of, contained in or derived from or any omission from this presentation, except liability under statute that cannot be excluded.

Warning Statement: A Prospectus is available for the TradePlus Shariah Gold Tracker and TradePlus S&P New China Tracker, while a Master Prospectus is available for the TradePlus NYSE® FANG+TM Daily (2x) Leveraged Tracker, TradePlus NYSE® FANG+TM Daily (-1x) Inverse Tracker, TradePlus HSCEI Daily (2x) Leveraged Tracker and TradePlus HSCEI Daily (-1x) Inverse Tracker (collectively known as the “TradePlus L&I ETFs”), and investors have the right to request a copy of it. Investors are advised to read and understand the contents of the Prospectus dated 28 November 2017 and Supplementary Prospectus dated 2 July 2019 (for TradePlus Shariah Gold Tracker), and Prospectus dated 15 January 2019 and Supplementary Prospectus dated 2 July 2019 (for TradePlus S&P New China Tracker), as well as the Master Prospectus dated 26 November 2019 (for the TradePlus L&I ETFs) before investing. The Prospectus / Supplementary Prospectus / Master Prospectus have been registered with the Securities Commission Malaysia, who takes no responsibility for its contents. An electronic copy of the Prospectus / Supplementary Prospectus / Master Prospectus can be obtained at Affin Hwang Asset Management Berhad’s website As with any forms of financial products, the financial products mentioned herein carries with them various risks. Investors are advised to consider the general and specific risks involved as stipulated in its Prospectus / Supplementary Prospectus / Master Prospectus before investing. There are also fees and charges involved when investing in these funds, and investors are advised to consider the fees and charges carefully before investing. The price of units and distribution payable, if any, may go down as well as up and past performance of the funds should not be taken as indicative of their future performance. 

Licensing Disclosure Statement & Conditions: The "S&P New China Ex A-Shares Index" is a product of S&P Dow Jones Indices LLC, a division of S&P Global, or its affiliates (“SPDJI”) and has been licensed for use by Affin Hwang Asset Management Bhd. Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC, a division of S&P Global (“S&P”); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”) and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Affin Hwang Asset Management Bhd. TradePlus S&P New China Tracker is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P New China Ex A-Shares Index.

Licensing Disclosure Statement & Conditions: Source ICE Data Indices, LLC (“ICE Data”), is used with permission. “NYSE® FANG+™” is a service/trade mark of ICE Data Indices, LLC or its affiliates and has been licensed, along with the NYSE® FANG+™ Daily 2X Leveraged Index and NYSE® FANG+™ Daily 1x Inverse Index (“Indices”) for use by Affin Hwang Asset Management Berhad in connection with the TradePlus NYSE® FANG+™ Daily (2x) Leveraged Tracker and the TradePlus NYSE® FANG+™ Daily (-1x) Inverse Tracker (the “Product”). Neither Affin Hwang Asset Management Berhad nor the Product, as applicable, is sponsored, endorsed, sold or promoted by ICE Data Indices, LLC, its affiliates or its Third Party Suppliers (“ICE Data and its Suppliers”). ICE Data and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally, in the Product particularly, or the ability of the Index to track general stock market performance. ICE Data’s only relationship to Affin Hwang Asset Management Berhad (“Licensee”) is the licensing of certain trademarks and trade names and the Index or components thereof. The Index is determined, composed and calculated by ICE Data without regard to the Licensee or the Product or its holders. ICE Data has no obligation to take the needs of the Licensee or the holder of the Product into consideration in determining, composing or calculating the Index. ICE Data is not responsible for and has not participated in the determination of the timing of, prices of, or quantities of the Product to be issued or in the determination or calculation of the equation by which the Product is to be priced, sold, purchased, or redeemed. Except for certain custom index calculation services, all information provided by ICE Data is general in nature and not tailored to the needs of Licensee or any other person, entity or group of persons. ICE Data has no obligation or liability in connection with the administration, marketing, or trading of the Product. ICE Data is not an investment advisor. Inclusion of a security within an index is not a recommendation by ICE Data to buy, sell, or hold such security, nor is it considered to be investment advice.